# Regeneron Pharmaceuticals, Inc. – Consensus ‘buy’ rating and 13.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/regeneron-pharmaceuticals-inc.consensus-buy-rating-and-13.5-upside-potential/4121131022
- Published: 2023-10-26T13:16:13+01:00
- Author: Charlotte Edwards

**Regeneron Pharmaceuticals, Inc.** which can be found using ticker (REGN) have 
now 21 confirmed analysts covering the stock with the consensus suggesting a rating
of ‘buy’. The target price High/Low ranges between 1064 and 680 suggesting an average
Analsyt target price of $912.52. Given that the stocks previous close was at $804.28
this would imply there is now a potential upside of 13.5%. There is a 50 day moving
average of $826.05 and the 200 moving average now moves to $776.49. The market capitalization
for the company is 86.53B. The stock price for the company is currently 797.04 USD

 The potential market cap would be $98,170,512,123 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 21.05, revenue per share of 118.47
and a 9.55% return on assets.

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers,
invents, develops, manufactures, and commercializes medicines for serious diseases.
Its commercialized medicines and product candidates in development are designed 
to help patients with eye diseases, allergic and inflammatory diseases, cancer, 
cardiovascular and metabolic diseases, pain, hematologic conditions, infectious 
diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection,
Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab)
Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza(
evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection,
ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept)
Injection for Intravenous Infusion. The Company also provides Expresse service assurance
and CloudCheck WiFi experience management solutions.

Share on: